Abstract:Rather than a "short-term tenant," the tumor microbiome has been shown to play a vital role as a "permanent resident," affecting carcinogenesis, cancer development, metastasis, and cancer therapies. As the tumor microbiome has great potential to become a target for the early diagnosis and treatment of cancer, recent research on the relevance of the tumor microbiota has attracted a wide range of attention from various scientific fields, resulting in remarkable progress that benefits from the development of interdisciplinary technologies. However, there are still a great variety of challenges in this emerging area, such as the low biomass of intratumoral bacteria and unculturable character of some microbial species. Due to the complexity of tumor microbiome research (e.g., the heterogeneity of tumor microenvironment), new methods with high spatial and temporal resolution are urgently needed. Among these developing methods, multi-omics technologies (combinations of genomics, transcriptomics, proteomics, and metabolomics) are powerful approaches that can facilitate the understanding of the tumor microbiome on different levels of the central dogma. Therefore, multi-omics (especially single-cell omics) will make enormous impacts on the future studies of the interplay between microbes and tumor microenvironment. In this review, we have systematically summarized the advances in multi-omics and their existing and potential applications in tumor microbiome research, thus providing an omics toolbox for investigators to reference in the future. In this review, we have systematically summarized the advances of multi-omics and their existing and potential applications in tumor microbiome research, thus providing an omics toolbox for investigators to reference in the future.image The tumor microbiome plays a significant role in carcinogenesis, cancer development, metastasis, and cancer therapies.The tumor microbiome has great potential to become a target for early diagnosis and treatment of cancer.Genomics, transcriptomics, proteomics, and metabolomics are powerful approaches for tumor microbiome studies, by facilitating an understanding of different levels of the central dogma.Multi-omics will make enormous impacts on future research of the tumor microbiome.The development of single-cell multi-omics technologies will motivate the progression of the tumor microbiome field.

Multi-level insights into the immuno-oncology-microbiome axis: From biotechnology to novel therapies

The Oncomicrobiome: New Insights into Microorganisms in Cancer

Applying Multi-Omics Toward Tumor Microbiome Research

Computational methods and challenges in analyzing intratumoral microbiome data.

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies

Emerging roles of the gut microbiota in cancer immunotherapy

A Multiomics Analysis of the Close Connection Between Intratumoral Microbiota and Immune Cell Infiltration in Colorectal Cancer.

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy

Broadening oncological boundaries: the intratumoral microbiota

The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies

The Emerging Tumor Microbe Microenvironment: from Delineation to Multidisciplinary Approach-Based Interventions

Influence of Microbiota on Tumor Immunotherapy

Multi-Omics Analysis Reveals Intratumor Microbes as Immunomodulators in Colorectal Cancer

Untangling determinants of gut microbiota and tumor immunologic status through a multi-omics approach in colorectal cancer

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy

Effects of intratumoral microbiota on tumorigenesis, anti-tumor immunity, and microbe-based cancer therapy

The critical role of tumor microbiome in cancer immunotherapy

Gut Microbiome in Modulating Immune Checkpoint Inhibitors.

Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy

Microbiota in cancer: molecular mechanisms and therapeutic interventions

Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes